• Something wrong with this record ?

Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity

Y. Cai, AM. Makarova, J. Wengel, KA. Howard,

. 2018 ; 20 (7-8) : e3025. [pub] 20180625

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19045443

BACKGROUND: Antisense gapmer oligonucleotide drugs require delivery and biodistribution enabling technologies to increase in vivo efficacy. An attractive approach is their binding and consequent transport by the endogenous human serum albumin pool as mediated by fatty acid incorporation into the gapmer design. METHODS: The present study investigated the effect of palmitoyl modification and position on albumin-binding, cellular uptake and in vitro gene silencing of gapmers with either a phosphorothioate (PS) or phosphodiester (PO) backbone. RESULTS: Two palmitoyls positioned exclusively at the 5' end, or a single palmitoyl at both the 3' and 5' positions, showed similar binding to human serum albumin as demonstrated by a gel-shift assay. Decreased cellular uptake determined by flow cytometry (27% compared to nonpalmitoyl gapmers) was observed for palmitoylated Cy5.5 labelled gapmers. However, HER3 (human epidermal growth factor receptor 3) gene silencing was exhibited by the palmitoylated gapmers with transfection agent in PC-3 and Caco-2 cells (68% and 62%, respectively), which was comparable to nonpalmitoyl gapmers (68% and 82%, respectively). Importantly, PO gapmers with a single palmitoyl positioned at both the 3' and 5' positions showed high silencing efficiencies (68% and 66% in PC-3 and Caco-2 cells, respectively) similar to those of PS nonpalmitoylated gapmers (67% and 66% in PC-3 and Caco-2 cells, respectively) in the absence of a transfection agent. CONCLUSIONS: The present study defines phosphodiester gapmer design criteria exhibiting high gene silencing activity and albumin binding that may be utilized with potentially less in vivo toxicity that can be associated with phosphorothioate gapmer designs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045443
003      
CZ-PrNML
005      
20200120085707.0
007      
ta
008      
200109s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jgm.3025 $2 doi
035    __
$a (PubMed)29800498
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cai, Yunpeng $u The Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.
245    10
$a Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity / $c Y. Cai, AM. Makarova, J. Wengel, KA. Howard,
520    9_
$a BACKGROUND: Antisense gapmer oligonucleotide drugs require delivery and biodistribution enabling technologies to increase in vivo efficacy. An attractive approach is their binding and consequent transport by the endogenous human serum albumin pool as mediated by fatty acid incorporation into the gapmer design. METHODS: The present study investigated the effect of palmitoyl modification and position on albumin-binding, cellular uptake and in vitro gene silencing of gapmers with either a phosphorothioate (PS) or phosphodiester (PO) backbone. RESULTS: Two palmitoyls positioned exclusively at the 5' end, or a single palmitoyl at both the 3' and 5' positions, showed similar binding to human serum albumin as demonstrated by a gel-shift assay. Decreased cellular uptake determined by flow cytometry (27% compared to nonpalmitoyl gapmers) was observed for palmitoylated Cy5.5 labelled gapmers. However, HER3 (human epidermal growth factor receptor 3) gene silencing was exhibited by the palmitoylated gapmers with transfection agent in PC-3 and Caco-2 cells (68% and 62%, respectively), which was comparable to nonpalmitoyl gapmers (68% and 82%, respectively). Importantly, PO gapmers with a single palmitoyl positioned at both the 3' and 5' positions showed high silencing efficiencies (68% and 66% in PC-3 and Caco-2 cells, respectively) similar to those of PS nonpalmitoylated gapmers (67% and 66% in PC-3 and Caco-2 cells, respectively) in the absence of a transfection agent. CONCLUSIONS: The present study defines phosphodiester gapmer design criteria exhibiting high gene silencing activity and albumin binding that may be utilized with potentially less in vivo toxicity that can be associated with phosphorothioate gapmer designs.
650    _2
$a albuminy $x metabolismus $7 D000418
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a umlčování genů $7 D020868
650    _2
$a lidé $7 D006801
650    _2
$a techniky in vitro $7 D066298
650    _2
$a lipoylace $7 D054878
650    _2
$a molekulární struktura $7 D015394
650    _2
$a antisense oligonukleotidy $x chemie $x genetika $x metabolismus $7 D016376
650    _2
$a vazba proteinů $7 D011485
650    _2
$a receptor erbB-3 $x genetika $7 D020893
650    _2
$a transfekce $7 D014162
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Makarova, Anna-Marie $u Faculty of Science, Charles University in Prague, Czech Republic.
700    1_
$a Wengel, Jesper $u Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark.
700    1_
$a Howard, Kenneth A $u The Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.
773    0_
$w MED00008737 $t The journal of gene medicine $x 1521-2254 $g Roč. 20, č. 7-8 (2018), s. e3025
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29800498 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200120090044 $b ABA008
999    __
$a ok $b bmc $g 1483712 $s 1084116
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 20 $c 7-8 $d e3025 $e 20180625 $i 1521-2254 $m The Journal of gene medicine $n J Gene Med $x MED00008737
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options